Abstract:Introduction: Hematological patients are at risk of infections. It is unknown whether the pathogenic microbial spectrum differs between HSCT and non-HSCT patients, and whether metagenomic next-generation sequencing (mNGS) of peripheral blood can be used as a substitute test specimen such as alveolar lavage. Methods: A retrospective study was conducted to evaluate the clinical application value of mNGS in hematological patients with and without HSCT. Results: Viruses were prevalent pathogens in both non-HSCT (44%) and HSCT (45%) patients, chiefly human cytomegalovirus and Epstein–Barr virus. In non-HSCT patients, Gram-negative bacilli accounted for 33% (predominantly Klebsiella pneumonia), and Gram-positive cocci accounted for 7% (predominantly Enterococcus faecium) of pathogens. However, in HSCT patients, Gram-negative bacilli accounted for 13% (predominantly Stenotrophomonas maltophilia), and Gram-positive cocci accounted for 24% (predominantly Streptococcus pneumonia) of pathogens. Mucor was the most common fungu s in two groups. The positive rate of pathogens by mNGS was 85.82%, higher than conventional detection (20.47%, P < 0.05). Mixed infection accounted for 67.00%, among which the mixed infection of bacteria and virus (25.99%) was the most common. 78 cases had pulmonary infection, the positive rate of traditional laboratory tests was 42.31% (33/78), and of mNGS in peripheral blood was 73.08% (57/78), showing a statistical difference (P = 0.000). The non-HSCT patients had a higher frequency of Klebsiella pneumonia (OR=0.777, 95% CI, 0.697-0.866, P = 0.01) and Torque teno virus (OR=0.883, 95% CI, 0.820-0.950, P = 0.031) infections than HSCT patients, while the rates of Streptococcus pneumonia (OR=12.828, 95% CI, 1.378-119.367, P = 0.016), Candida pseudosmooth (OR=1.100, 95% CI, 0.987-1.225, P = 0.016), human betaherpesvirus 6B (OR=6.345, 95% CI, 1.105-36.437, P = 0.039) and human polyomavirus 1 (OR=1.100, 95% CI, 0.987-1.225, P = 0.016) infections were lower. Leishmania could be detected by mNGS. Conclusion: mNGS of peripheral blood can be used as a substitute test method for hematological patients with pulmonary infection, the detection rate of mixed infections by mNGS was high, and mNGS has high clinical recognition rate and sensitivity in pathogen detection, and provides a basis for guiding the anti-infective treatment in hematological diseases with symptoms such as fever.

Next-generation sequencing for hypothesis-free genomic detection of invasive tropical infections in poly-microbially contaminated, formalin-fixed, paraffin-embedded tissue samples – a proof-of-principle assessment

Application of Next Generation Sequencing Technology on Contamination Monitoring in Microbiology Laboratory

Next-Generation Sequencing Applications for the Study of Fungal Pathogens

Next-generation Sequencing in Neuropathologic Diagnosis of Infections of the Nervous System.

Impact of next-generation sequencing on antimicrobial treatment in immunocompromised adults with suspected infections

Using next generation sequencing to study host-pathogen interactions

Development and Optimization of an Unbiased, Metagenomics-Based Pathogen Detection Workflow for Infectious Disease and Biosurveillance Applications

Clinical PathoScope: rapid alignment and filtration for accurate pathogen identification in clinical samples using unassembled sequencing data

Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids

Fungal Whole-Genome Sequencing for Species Identification: From Test Development to Clinical Utilization

Enhancing ascitic fungal infection diagnosis through next-generation sequencing: a pilot study in surgical ICU patients

Detection of Pathogenic Microbe Composition Using Next-Generation Sequencing Data

Pathogenic Detection by Metagenomic Next-generation Sequencing in Skin and Soft Tissue Infection

Toward Accurate Diagnosis and Surveillance of Bacterial Infections Using Enhanced Strain-Level Metagenomic Next-Generation Sequencing of Infected Body Fluids.

Sanger Sequencing Implementation in Clinically Ill Patients for Bacterial and Fungal Pathogens Identification

Application of next-generation sequencing to identify different pathogens

An integrated method for targeted Oxford Nanopore sequencing and automated bioinformatics for the simultaneous detection of bacteria, fungi, and ARG

A streamlined clinical metagenomic sequencing protocol for rapid pathogen identification

Analytical Performance Validation of Next-Generation Sequencing Based Clinical Microbiology Assays Using a K-mer Analysis Workflow

Application of metagenomic next-generation sequencing in the diagnosis of pulmonary invasive fungal disease

Clinical application value of metagenomic second-generation sequencing technology in hematologic diseases with and without transplantation